Submissions

Login or Register to make a submission.

Author Guidelines

All submissions will be evaluated by an editor to determine if they meet the journal's objectives and scope. Those considered suitable will undergo peer review before a final decision on acceptance or rejection is made.

 

ORIGINAL INVESTIGATIONS

These are unpublished manuscripts on new discoveries in Vision Sciences, encompassing a wide range of clinical and/or laboratory research topics. They must meet the following criteria:


- The research topic must be novel, engaging, and make a valuable contribution to the field.
- Abstract Sections: Relevance (maximum 50 words), Purpose, Methods, Results, Conclusions, and Keywords (up to 5). The total abstract length should not exceed 500 words.
- Main Text Sections: Introduction, Methods, Results, Discussion, Conclusions, Conflict of Interest Statement, References, and Abbreviations.
- Clear and concise content: Maximum of 4000 words and 35 references.
- Maximum number of figures: 5.
- Maximum number of tables: 5.
- Methodology must be clear, rigorous, and reproducible.
- Results should focus on study objectives and present original observations.
- Results must include measures of central tendency (e.g., mean or median) with variability estimates (e.g., standard deviation, confidence intervals, quartiles, etc.)
- All conclusions must be supported by the data.

IMPORTANT
- Submit 2 Word documents:
  - Main text with title but WITHOUT authors' names or affiliations.
  - A separate Word document with the article title and the full names and affiliations of all authors.
- Conflict of Interest Statement: The corresponding author is responsible for identifying and clearly disclosing any financial relationships involving all coauthors that may influence the research results. A "Conflict of Interest" section must be included after the manuscript text and before the references, specifying how any companies or sponsors contributed to the research (e.g., translation, study design, data collection, analysis, management, etc.). If no funding or conflicts exist, this should also be stated clearly in this section. Failure to provide a clear conflict of interest statement may result in manuscript rejection.
- For research involving human subjects, the following statement must be included in the Methods section: This research was reviewed by an independent Ethics Committee and complies with applicable principles and guidelines for protecting human subjects in biomedical research.

 

   SYSTEMATIC REVIEWS

These provide high-level evidence in clinical research by synthesizing numerous scientific bibliographic sources on a specific topic. They can offer a summary, perspective, or synthesis useful to the scientific community.
Review Articles must adhere to the following guidelines:
- Abstract Sections: Relevance (maximum 50 words), no specific additional sections (DO NOT include purpose, materials, methods, etc.). Keywords (up to 5). The total abstract length should not exceed 500 words.
- Main Text Sections: Introduction, Discussion, Conclusions, Conflict of Interest Statement, References, and Abbreviations.
- Clear and concise content: Maximum of 4000 words and 80 references.
- Maximum number of figures: 5.
- Maximum number of tables: 5.
- All conclusions must be supported by data.

IMPORTANT
- Submit 2 Word documents:
  - Main text with title but WITHOUT authors' names or affiliations.
  - A separate Word document with the article title and the full names and affiliations of all authors.
- Conflict of Interest Statement: The corresponding author is responsible for identifying and clearly disclosing any financial relationships involving all coauthors that may influence the research results. A "Conflict of Interest" section must be included after the manuscript text and before the references, specifying how any companies or sponsors contributed to the research (e.g., translation, study design, data collection, analysis, management, etc.). If no funding or conflicts exist, this should also be stated clearly in this section. Failure to provide a clear conflict of interest statement may result in manuscript rejection.
- For research involving human subjects, the following statement must be included in the Methods section: This research was reviewed by an independent Ethics Committee and complies with applicable principles and guidelines for protecting human subjects in biomedical research.

 

   CASE REPORTS AND CASE SERIES
Case reports may serve as sources of new ideas and observations, prompting further clinical or laboratory studies. These reports and case series are brief discussions highlighting relevant clinical findings, complex diagnoses, interesting treatment techniques, clinical technologies, etc., that may interest the scientific community. Cases should be well-documented, with adequate follow-up to support conclusions drawn.

Case reports/case series should follow these guidelines:
- Abstract Sections: Relevance (maximum 50 words), Purpose, Clinical Case Report(s), Conclusions, and Keywords (up to 5). The total abstract length should not exceed 500 words.
- Main Text Sections: Relevance of Cases, Clinical Case 1 (2, 3…), Conclusions, Conflict of Interest Statement, References, and Abbreviations.
- Clear and concise content: Maximum of 2500 words and 20 references.
- Maximum number of figures: 5.
- Maximum number of tables: 5.

IMPORTANT
- Submit 2 Word documents:
  - Main text with title but WITHOUT authors' names or affiliations.
  - A separate Word document with the article title and the full names and affiliations of all authors.
- Conflict of Interest Statement: The corresponding author must identify and clearly disclose any financial relationships involving all coauthors that may influence the research results. A "Conflict of Interest" section must be included after the manuscript text and before the references, detailing any company or sponsor contributions (e.g., translation, study design, data collection, analysis, management, etc.). If no funding or conflicts exist, this should be stated clearly. An unclear conflict of interest statement may result in manuscript rejection.
- For research involving human subjects, the following statement must be included in the Methods section: This research was reviewed by an independent Ethics Committee and complies with applicable principles and guidelines for protecting human subjects in biomedical research.

 

CLINICAL TRIALS
Clinical trials are defined as prospective studies in which subjects are assigned to an intervention to study cause-effect relationships between the intervention and a specific health outcome. Transparency, rigor, and reproducibility are essential in clinical trials. Well-designed, conducted, and reported clinical trials form the basis for evidence-based clinical practice. The following is required to ensure rigor and transparency when reporting clinical trial results:
Authors must register clinical trials in ClinicalTrials.gov or with a WHO ICTRP primary registry affiliate.
Following the guidelines of the International Committee of Medical Journal Editors (ICMJE), this journal will only publish results from clinical trials registered before the enrollment of the first subject. The registry, registration date, and registration number must be provided on the title page when submitting the manuscript.
Authors reporting clinical trial results to this journal must comply with CONSORT guidelines. Authors should use the recommended checklist and flowchart available on the organization's website (www.consort-statement.org).

 

LETTERS TO THE EDITOR
These are brief letters to the Editorial Committee on a specific topic, contributing academically and meaningfully to scientific community discussions. Letters may address recently published articles, interesting scientific reflections, viewpoints on recent developments relevant to the field, etc.
- Letter text should not exceed 500 words.

 

WRITING AND FORMATTING GUIDELINES
Documents:
- Microsoft Word documents (.doc/.docx).
- A4 page size (21.0 x 21.7 cm) with 2.54 cm top, bottom, and side margins.
- Arial font, 11-point size.
- 2-point line spacing, with consecutively numbered lines (Page Layout/Line Numbers). Line numbering in the manuscript text file should stop at the references. Do not add line numbers on the title page, abstract, references, tables, and figures.

Abbreviations and Symbols:
- When abbreviating one or more words, define the full word(s) the first time they appear in the text, followed by the abbreviation in parentheses. Example: Uncorrected Visual Acuity (UVA). Thereafter, only the abbreviation should be used throughout the text. This rule applies separately to both the abstract and the main body of the research. Do not include abbreviations in the title.
- Add a section at the end of the text (after the References) listing all abbreviations used and their explanations.
- When using instruments, materials, medications, etc., produced by commercial companies, the trade name must be followed by the registered trademark symbol ® and the company and country of production in parentheses. This is required only the first time it appears in the text; subsequently, only the trade name with the registered trademark symbol ® is necessary.

Expressing Values:
- Use the International Metric System for units of measurement. Diopter notations should follow this format: -1.00 D sphere -1.00 D cylinder x 90º. Measurements should be spaced from numeric values (e.g., 22.31 mm).
- Decimals should be written with commas in Spanish and periods in English. The same decimal format should be used consistently within the same group of measurements. For values much smaller than zero, consider scientific notation (e.g., 3·10^-6).
- Statistical significance values should be written with a capital, italicized "P," followed by the exact numerical value with two decimal places if equal to or greater than 0.05, or the appropriate "<" symbol and threshold (e.g., P = 0.33; P < 0.05; P < 0.01).

Tables, Graphs, Figures, Photographs:
- If the work includes data tables, use Microsoft Word tables without formatting, and insert them in the text where publication is desired, followed by a caption beneath the table.
- If the work includes graphs, figures, or photographs, they should be in .TIFF, .JPG, or .PNG format, with a minimum resolution of 300 dpi. Insert the figures, graphs, or photographs directly in the text where publication is desired, followed by a caption beneath the figure.
- Arial font is recommended if your graph, figure, or photograph includes text and/or numbers.
- All tables, figures, graphs, or photographs must include a caption beneath them, centered and separated. The caption should include the table, figure, graph, or photograph number in bold, title, subtitle (if needed), and explanation of any abbreviations appearing in the table, figure, graph, or photograph, in italics on a new line, separated by semicolons. Example:
   Figure 1: Visual Field.
   MD: Mean Deviation; PSD: Pattern Standard Deviation; VFI: Visual Field Index.

References:
- We recommend using a reference management program (Mendeley, RefWorks, EndNote, etc.)
- References cited in the main body should be written using numbers in parentheses at the end of the referenced text, leaving a space, in order of appearance. Example: (1); (3-5); (4,6-8).
- The final section of the manuscript should be References, where the numbers cited throughout the text are listed, followed by the corresponding bibliographic reference in Vancouver style. Limit the number of authors to three. If a reference has more than three authors, list the first three followed by et al. Do not include web links in any reference. Examples:

  1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–83.
  2. Abelson MB, Udell IJ, Weston JH. Normal human tear ph by direct measurement. Arch Ophthalmol [Internet]. 1 Feb 1981 [citado 9 Jul 2019];99(2):301.
  3. Simmons PA, Vehige JG. Clinical performance of a mid-viscosity artificial tear for dry eye treatment. Cornea. Abr 2007;26(3):294–302.
  4. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. Handbook of pharmaceutical excipients, Sixth edition. London; 2009. 706-714.

Post-publication discussions and corrections

Authors may request by e-mail editorial@revistaoccv.com specific corrections in the published version of their work, provided that these do not modify the pagination of the journal or imply substantial changes in the approach or subject of the work.

Submission Preparation Checklist

All submissions must meet the following requirements.

  • Main text does NOT contain any author name neither affiliations.
  • This submission meets the requirements outlined in the Author Guidelines.
  • This submission has not been previously published, nor is it before another journal for consideration.
  • All references have been checked for accuracy and completeness.
  • All tables and figures have been numbered and have legend in their bottom.
  • Permission has been obtained to publish all photos, datasets and other material provided with this submission.

Original Investigations

These are unpublished manuscripts on new discoveries in Vision Sciences, encompassing a wide range of clinical and/or laboratory research topics. They must meet the following criteria:


- The research topic must be novel, engaging, and make a valuable contribution to the field.
- Abstract Sections: Relevance (maximum 50 words), Purpose, Methods, Results, Conclusions, and Keywords (up to 5). The total abstract length should not exceed 500 words.
- Main Text Sections: Introduction, Methods, Results, Discussion, Conclusions, Conflict of Interest Statement, References, and Abbreviations.
- Clear and concise content: Maximum of 4000 words and 35 references.
- Maximum number of figures: 5.
- Maximum number of tables: 5.
- Methodology must be clear, rigorous, and reproducible.
- Results should focus on study objectives and present original observations.
- Results must include measures of central tendency (e.g., mean or median) with variability estimates (e.g., standard deviation, confidence intervals, quartiles, etc.)
- All conclusions must be supported by the data.

IMPORTANT
- Submit 2 Word documents:
  - Main text with title but WITHOUT authors' names or affiliations.
  - A separate Word document with the article title and the full names and affiliations of all authors.
- Conflict of Interest Statement: The corresponding author is responsible for identifying and clearly disclosing any financial relationships involving all coauthors that may influence the research results. A "Conflict of Interest" section must be included after the manuscript text and before the references, specifying how any companies or sponsors contributed to the research (e.g., translation, study design, data collection, analysis, management, etc.). If no funding or conflicts exist, this should also be stated clearly in this section. Failure to provide a clear conflict of interest statement may result in manuscript rejection.
- For research involving human subjects, the following statement must be included in the Methods section: This research was reviewed by an independent Ethics Committee and complies with applicable principles and guidelines for protecting human subjects in biomedical research.

Clinical Cases and Case Series

Case reports can be a source of new ideas and observations that stimulate future clinical or laboratory studies. Case reports and case series are brief discussions that highlight relevant clinical findings, complicated diagnoses, interesting treatment techniques, clinical technologies, etc., which would be of interest to the scientific community.

Cases must be well-documented with an adequate duration of follow-up to support the conclusions made.

Case reports/case series should follow these guidelines:
- Abstract Sections: Relevance (maximum 50 words), Purpose, Clinical Case Report(s), Conclusions, and Keywords (up to 5). The total abstract length should not exceed 500 words.
- Main Text Sections: Relevance of Cases, Clinical Case 1 (2, 3…), Conclusions, Conflict of Interest Statement, References, and Abbreviations.
- Clear and concise content: Maximum of 2500 words and 20 references.
- Maximum number of figures: 5.
- Maximum number of tables: 5.

IMPORTANT
- Submit 2 Word documents:
  - Main text with title but WITHOUT authors' names or affiliations.
  - A separate Word document with the article title and the full names and affiliations of all authors.
- Conflict of Interest Statement: The corresponding author must identify and clearly disclose any financial relationships involving all coauthors that may influence the research results. A "Conflict of Interest" section must be included after the manuscript text and before the references, detailing any company or sponsor contributions (e.g., translation, study design, data collection, analysis, management, etc.). If no funding or conflicts exist, this should be stated clearly. An unclear conflict of interest statement may result in manuscript rejection.
- For research involving human subjects, the following statement must be included in the Methods section: This research was reviewed by an independent Ethics Committee and complies with applicable principles and guidelines for protecting human subjects in biomedical research.

Systematic Reviews

These provide high-level evidence in clinical research by synthesizing numerous scientific bibliographic sources on a specific topic. They can offer a summary, perspective, or synthesis useful to the scientific community.
Review Articles must adhere to the following guidelines:
- Abstract Sections: Relevance (maximum 50 words), no specific additional sections (DO NOT include purpose, materials, methods, etc.). Keywords (up to 5). The total abstract length should not exceed 500 words.
- Main Text Sections: Introduction, Discussion, Conclusions, Conflict of Interest Statement, References, and Abbreviations.
- Clear and concise content: Maximum of 4000 words and 80 references.
- Maximum number of figures: 5.
- Maximum number of tables: 5.
- All conclusions must be supported by data.

IMPORTANT
- Submit 2 Word documents:
  - Main text with title but WITHOUT authors' names or affiliations.
  - A separate Word document with the article title and the full names and affiliations of all authors.
- Conflict of Interest Statement: The corresponding author is responsible for identifying and clearly disclosing any financial relationships involving all coauthors that may influence the research results. A "Conflict of Interest" section must be included after the manuscript text and before the references, specifying how any companies or sponsors contributed to the research (e.g., translation, study design, data collection, analysis, management, etc.). If no funding or conflicts exist, this should also be stated clearly in this section. Failure to provide a clear conflict of interest statement may result in manuscript rejection.
- For research involving human subjects, the following statement must be included in the Methods section: This research was reviewed by an independent Ethics Committee and complies with applicable principles and guidelines for protecting human subjects in biomedical research.

Clinical Trials

Clinical trials are defined as prospective studies in which subjects are assigned to an intervention to study cause-effect relationships between the intervention and a specific health outcome. Transparency, rigor, and reproducibility are essential in clinical trials. Well-designed, conducted, and reported clinical trials form the basis for evidence-based clinical practice. The following is required to ensure rigor and transparency when reporting clinical trial results:
Authors must register clinical trials in ClinicalTrials.gov or with a WHO ICTRP primary registry affiliate.
Following the guidelines of the International Committee of Medical Journal Editors (ICMJE), this journal will only publish results from clinical trials registered before the enrollment of the first subject. The registry, registration date, and registration number must be provided on the title page when submitting the manuscript.
Authors reporting clinical trial results to this journal must comply with CONSORT guidelines. Authors should use the recommended checklist and flowchart available on the organization's website (www.consort-statement.org).

Letters to the Editor

They are brief letters to the Editorial Committee on a specific topic. They should make an academic and useful contribution to the debates within the scientific community. Letters may address recently published articles, interesting scientific reflections, views on recent advances of importance to the field, etc.

The text of the Letter to the Editor must not exceed 500 words.

Copyright Notice

By submitting an article, all authors agree to our copyright policy. All articles will conform to the Creative Commons Attribution-NonCommercial 4.0 license. You can review our policy at this link.

Privacy Statement

In compliance with the Spanish Law 34/2002 on Information Society Services and Electronic Commerce of Spain, we inform you that this website is owned by the ARAGONESA SOCIETY OF OPTOMETRY AND CONTACTOLOGY, with registered address at 15 Cadena Street, Zaragoza, and VAT number G-99557373, and whose contact email is cooaragon@gmail.com.

This website, www.revistaoccv.com ("Website"), is governed by Spanish regulations, to which all its users expressly submit (hereinafter, "User").

Access to the Website by any User is free and conditioned upon prior reading and full, express, and unconditional acceptance of the Legal Notice and the Privacy Policy that may be applicable at the time of each access and use of the Website. All published articles will comply with the Creative Commons Non-Commercial 4.0 license.

Consequently, all Users:

Agree to carefully read both the Legal Notice and the Privacy Policy

Agree to accept and expressly submit to what is established in the Legal Notice and the Privacy Policy

If the User does not agree with the Legal Notice or the Privacy Policy, they must immediately refrain from using or in any way operating on this Website.

Users accept that the presentation and configuration of this Website, as well as its services and contents, may be modified or even deleted unilaterally and without prior notice by SAOCO.

Intellectual and industrial property rights over the Website: All content, texts, images, and source codes are protected by applicable legislation on intellectual and industrial property and are the exclusive property of SAOCO, or, where applicable, of third parties from whom SAOCO has obtained the corresponding exploitation license.

The User shall only have the right to make private and non-commercial use of the content, texts, and images included on the Website, without profit, and shall require express authorization from SAOCO and/or, where applicable, the corresponding rights holder to modify, reproduce, exploit, distribute, or exercise any other right owned by SAOCO or, where applicable, a third party.

Conditions of access to the Website: Access to the Website is free and does not require prior subscription or registration by Users. However, SAOCO reserves the right to offer services or content that require prior registration by the User, and, where applicable, payment of a price. In any case, these services and contents shall be duly and clearly identified on the Website.

All Users must access the Website in good faith, in accordance with applicable law, public order, the Legal Notice, and the Privacy Policy. Access and use of the Website are carried out under the sole and exclusive responsibility of the User, who shall be liable in any case for any damages and losses that may be caused by said access or use to third parties or to SAOCO.

Users shall be liable for any damages and losses of any kind that SAOCO may suffer as a result of the User's breach of any of the obligations established in this Legal Notice or the Privacy Policy.

Users shall indemnify SAOCO in the event of any sanction, claim, or lawsuit against SAOCO for the infringement of third-party rights or applicable regulations when accessing or using the Website contrary to the provisions of this Legal Notice.

Disclaimer: SAOCO makes every effort to ensure that the information and content available on the Website are up-to-date and that the Website is available at all times. However, SAOCO cannot guarantee that the Website will be updated at all times and free of errors, nor its rapid and uninterrupted use. In particular, for example, SAOCO disclaims liability in the following cases:

Technical failures that, for any reason, prevent the normal operation of the Website;

Lack of availability of the Website due to maintenance or other reasons, preventing access to the service;

Damages arising from computer viruses and similar, or generated as a result of improper use of the Website.

Third-party interference in the service. Without prejudice to the technical measures that may be taken to reduce this type of risk, SAOCO assumes no liability for damages that may be caused to the User for this reason.

Legal Notice Updates: SAOCO reserves the right to modify the Legal Notice and the Privacy Policy at any time. When significant changes are made to this Legal Notice or the Privacy Policy, SAOCO will communicate them to Users through the Website to offer them the possibility of reviewing the changes made. Users must refrain from using the Website if they do not agree with the updates made to the Legal Notice or the Privacy Policy.

PERSONAL DATA PROTECTION POLICY

  1. APPENDIX I. LEGAL NOTICE

1.- Legal Information

www.revistaoccv.com and www.revistaoccv.es (hereinafter, the WEBSITE) are two domains registered by NATIONAL COLLEGE OF OPTICIANS-OPTOMETRISTS with VAT Q2877036J (hereinafter NCOO) with corporate address at 25 Princesa Street, 28008 Madrid for the use and management of its ARAGON DELEGATION with address at 15 Cadena Street, 50001, Zaragoza.

2.- Nature of the services

Access to the WEBSITE is free of charge, without prejudice to the fact that the contracting of products or services through the WEBSITE may be subject to an economic consideration.

3.- USER responsibility

The USER undertakes not to use the WEBSITE or the information offered therein for activities contrary to the Law, morals, or public order and, in general, to make use in accordance with the conditions established by NCOO.

The opinions, content, and, in general, all activities carried out by the USER, are their sole responsibility, without NCOO being liable for any damages or losses that may arise from such activities beyond its control and without it having effective knowledge of them.

4.- NCOO responsibility

NCOO shall not be responsible for errors in accessing the WEBSITE or its contents, although it shall make every effort to ensure that such errors do not occur.

NCOO reserves the right to temporarily suspend, without prior notice, access to the WEBSITE for the purpose of carrying out maintenance, repair, updating, or improvement operations.

5.- Intellectual and Industrial Property

All contents of the WEBSITE (including, without limitation, databases, images, drawings, graphics, text files, audio, video, and software) are the property of NCOO and are protected by national and international laws on intellectual and industrial property, all rights reserved.

The domain name, trademarks, labels, distinctive signs, or logos appearing on the WEBSITE are the property of NCOO.

All texts, graphic designs, videos, or audio supports that may be found at this time or in the future on this Internet site are the property of NCOO and may not be subject to further modification, copying, alteration, total or partial reproduction, adaptation, or translation by the USER or third parties without the express authorization of NCOO.

Unauthorized use of the information contained on this WEBSITE, as well as infringement of intellectual or industrial property rights, will give rise to legally established responsibilities.

6.- Hyperlinks

The establishment of any hyperlink from a third-party website to any of the pages of the NCOO WEBSITE will be subject to the following conditions:

- Reproduction, either in whole or in part, of any of the services contained on the NCOO WEBSITE is not permitted.

- No false, inaccurate, or incorrect statements about the pages of the NCOO WEBSITE and its services will be included.

- Under no circumstances will NCOO be responsible for the content, information, statements, opinions, or services made available to the public on the website from which a hyperlink to this WEBSITE is established.

- Any hyperlink will be directed to the main page of the WEBSITE.

The hyperlinks found on the WEBSITE have been previously agreed upon with the owners of the linked websites. NCOO will not be responsible for the misuse or activities contrary to law, morals, or public order carried out by users on such linked pages.

7.- Validity of the terms of use

The terms of use of this WEBSITE are indefinite. NCOO reserves the unilateral right to modify the conditions of access to them, as well as their content.

8.- Nullity and ineffectiveness of clauses

If any clause included in these conditions were to be declared totally or partially null or ineffective, such nullity will only affect said provision or the part thereof that is null or ineffective, with all other conditions remaining in full force.

9.- Applicable legislation and jurisdiction

The provision of the service of this WEBSITE and these terms of use are governed by Spanish law.

Any contentious issue arising from the services provided through this WEBSITE will be resolved through consumer arbitration tribunals, mediators, or similar entities to which NCOO is adhered at the time of the dispute, as well as the corresponding courts and tribunals in accordance with Spanish legislation.

  1. ANNEX II. PRIVACY POLICY

1.- Identity of the Data Controller

The information provided by the USER through any of the forms on the WEBSITE will be included in one or more files the responsibility of the National College of Opticians-Optometrists (VAT Q2877036J) with corporate address at 25 Princesa Street, 28008 Madrid, managed through its ARAGON DELEGATION.

2.- Purpose of the processing

NCOO will process the information provided by the USER for various purposes, depending on the method of data collection:

- Manage the contractual or commercial relationship established between NCOO and the USER.

- Provide the services requested by the USER.

- Manage, administer, provide, expand, and improve the services to which the USER has decided to subscribe or register.

- Adapt such services to improve their quality for the USER.

- Design new services related to the above.

- Conduct statistical studies to design improvements in the services provided.

- Send information requested by the USER.

- Send information about modifications to the products or services contracted by the USER.

- Send information about new products or services in the Optical and Audiology sectors, similar to those originally contracted or that may be of interest to the USER through any means, including electronic means, even after the commercial relationship between NCOO and the USER ends.

The USER consents to the processing of their data for the purposes described, without prejudice to the right to revoke said consent by emailing dr11@cnoo.es, identifying themselves as a USER of the WEBSITE, and specifying their request or, where appropriate, by checking the box provided for this purpose on the form itself.

3.- Recipients of the information

The data provided by the USER to NCOO will not be communicated to any third party, unless:

- The transfer is authorized by law.

- The processing responds to the free and legitimate acceptance of a legal relationship whose development, compliance, and control necessarily involve the connection of said processing with files of third parties, such as banking entities for the billing of contracted products or services or courier companies for the delivery of contracted products.

- The data is requested by the Ombudsman, the Public Prosecutor's Office, or the Courts or Tribunals or the Court of Auditors, in the exercise of the functions attributed to them.

4.- Mandatory or optional nature of the requested information

The mandatory data of each form will be identified as such in the form itself.

The refusal to provide such information will prevent the effective provision of the service requested by the USER.

5.- Exercise of rights

The USER may exercise their rights of access, rectification, cancellation, and opposition by emailing dr11@cnoo.es, identifying themselves as a USER of the WEBSITE, and specifying their request.

The USER may also exercise their rights of access, rectification, cancellation, and opposition by ordinary mail to the address at Calle Cadena, 15, 50001, Zaragoza, identifying themselves as a USER of the WEBSITE, providing a photocopy of their ID or equivalent document, and specifying their request.

6.- USER commitments

- The USER guarantees that they are over 14 years of age and that the information provided is accurate and truthful.

- The USER agrees to inform NCOO of any changes to the information provided by emailing dr11@cnoo.es, identifying themselves as a USER of the WEBSITE, and specifying the information that needs to be modified.

- Likewise, the USER agrees to keep the passwords and identification codes secret and to inform NCOO immediately in case of loss, theft, or unauthorized access. Until such communication is made, NCOO will be exempt from any liability that may arise from the misuse by unauthorized third parties of such passwords and identification codes.

7.- Third-party data provided by the USER

If the USER provides personal data of third parties for any purpose, they guarantee to have previously informed the affected parties and obtained their consent for the communication of their data to NCOO.

The USER guarantees that the affected parties are over 14 years of age and that the information provided is accurate and truthful.

NCOO will verify the consent of said affected parties through an initial non-commercial email requesting verification of the consent granted on their behalf by the USER.

In the event that liabilities arise from a breach of these conditions by the USER, they will be responsible for the consequences of such breach.

  1. Cookie Policy and Tracking Files

In addition to those strictly necessary cookies for web browsing, such as session cookies, this website may use analytical and advertising cookies, both its own and from third parties (Google Analytics services), which allow storing information in the user's browser, retrievable in subsequent visits.

Google Analytics services are used to measure and analyze website visits. The data obtained will be processed by Google in accordance with the Google Analytics Privacy Policy. Therefore, any rights related to Google's cookies should be exercised by directly contacting the responsible parties of this website as indicated in said Privacy Policy.

Cookies will not be installed on your computer until you express your willingness to browse the web through one of the following actions:

- Staying on the website for more than 15 seconds.

- Scrolling vertically through the website.

- Clicking on any point or link on the website.

By taking any of these actions, the USER accepts the use of cookies and IP tracking files, the use of which allows CNOO to collect data for statistical purposes such as: date of the first visit, number of visits, date of the last visit, URL and domain of origin, browser used, and screen resolution.

In any case, the USER may prevent the installation of cookies or delete those already installed through the configuration of their browser, as well as through the use of specific applications. However, CNOO is not responsible for any malfunction of the page resulting from their deactivation. The information obtained is completely anonymous and cannot be associated with a specific identified user.

Here are the instructions for configuring cookies in the main browsers:

Chrome: Settings -> Show advanced settings -> Privacy -> Content settings. For more information, you can consult Google's support or the browser's Help.

Firefox: Tools -> Options -> Privacy -> History -> Custom Settings. For more information, you can consult Mozilla's support or the browser's Help.

Internet Explorer: Tools -> Internet Options -> Privacy -> Settings. For more information, you can consult Microsoft's support or the browser's Help.

Safari: Preferences -> Security. For more information, you can consult Apple's support or the browser's Help.

  1. Security Measures

CNOO has adopted the necessary technical and organizational measures to guarantee the security of personal data and prevent its alteration, loss, treatment, or unauthorized access, taking into account the state of technology, the nature of the data stored, and the risks to which they are exposed, whether from human action or physical or natural means.

However, the USER should be aware that security measures on the Internet are not impregnable.

  1. ANNEX III. LEGAL TERMS AND CONDITIONS OF SWEEPSTAKES AND CONTESTS

To consult the legal terms and conditions of sweepstakes and contests organized by the College of Opticians-Optometrists of Aragon through its social media channels, click here.